gi-4000
mCRC
ImmunityBio, Inc.vaccinePhase 1/2Dormant
C
39/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 25/ 100
- Competitive Position
- 81/ 100
Competitive context
12 Active assets in the mCRC cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Calcium folinate pentahydrate Shanghai Henlius Biotech | Phase 2 | B |
FLUOROURACILUM Shanghai Henlius Biotech | Phase 2 | B |
Eloxatin Shanghai Henlius Biotech | Phase 2 | B |
(+)-VINCRISTINE Oncolytics Biotech | Phase 2 | CCC |
Pelareorep Oncolytics Biotech | Phase 2 | CCC |
View all 20 →
Same molecule, other indications
gi-4000 is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →